Get actionable insights on how COVID-19 is impacting your business sector.Enquire now
Bruton's tyrosine kinase (Btk) is a member of the Tec family of cytoplasmic protein tyrosine kinases (PTK). BTK enzyme is encoded by the BTK gene. It is expressed in the cells of all hematopoietic lineages except for T and plasma cells. The protein kinase BTK is implicated in the development, differentiation, and activation of B cells through its role in the BCR and TLR signaling cascades. Clinical evidence indicates loss-of-function mutations in BTK result in X-linked agammaglobulinemia and cancers. Thus BTK has emerged as a novel anticancer target for the treatment of B-cell lymphomas and leukemias.
Currently, marketed anti-BTK drug is Imbruvica (ibrutinib). It is indicated for the treatment of graft versus host disease, hematological malignancies, and Non-Hodgkin’s lymphoma.
Pipeline activity of BTK inhibitors is quite dynamic. Several BTK inhibitors candidates more than 20 are in late stage clinical trials and are expected to achieve the regulatory approval in the near future which includes GDC-0834, GDC-0834, RN486, TP-4207, PCI-45261, BGB-3111, PCI 45292, ABBV-105, PRN1008, HCI-1401, EBI-1367, EBI-1266, SNS-062, RG7845, and GDC-0853. Preclinical and early clinical results indicate that these inhibitors are useful for the treatment of lymphomas and leukemias. The companies which are involved in the development of BTK inhibitors are Gilead, Roche, AbbVie, J&J, Eli Lilly, AstraZeneca, and Biogen.
Reasons to Buy
- To gain erudite insights about the Bruton's tyrosine kinase (BTK) inhibitors pipeline landscape
- To ascertain unique product development dynamics and leverage it for new target identification, drug repositioning, and precision medicine
- To optimize the pipeline product portfolio in correspondence with the dynamic pharmaceutical market
- To identify competitors and design strategic initiatives for drug development activities
- To understand the market and choose right partners for strategic collaborations
- To obtain informed updates on drug termination/drug discontinuation
FILL IN YOUR DETAILS BELOW TO GET FREE SAMPLE OF THIS REPORT
Our reports have been used by over 10K customers, including:
CEO, Co-founder Audink Inc., DBA Audios
The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow.
Senior Product Manager Interstates
I recently purchased a key Arizton Industry Outlook & Forecast in order to better understand growth for specific market segments and the macro environmental factors impacting this growth. I found Arizton’s coverage of the market dynamics and key takeaways to be insightful and valuable. The segmentation breakouts gave me the information I needed to guide strategic considerations.
Manager Market Analyst Power
Generation & Energy Rolls-Royce Power Systems AG
The provided information by Arizton really met my expectations. Especially the deep information about the datacenter ecosystem was very helpful. Furthermore, I absolutely appreciate the optimal service from the key account managers of Arizton. It was always a pleasure working with them.